

## PRESIDENCY

**Paolo A. Ascierto** | Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy

**Francesco M. Marincola** | Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

**Nicola Mozzillo** | Director of the Department of Melanoma and Soft Tissue, Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy

## SCIENTIFIC BOARD

**Paolo A. Ascierto** | Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy

**Gennaro Ciliberto** | Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy

**Reinhard Dummer** | University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

**Bernard A. Fox** | Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

**Claus Garbe** | Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen (Stuttgart), Germany

**John M. Kirkwood** | Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute, Pennsylvania

**Francesco M. Marincola** | Sidra Medical and Research Centre, Doha, Qatar

**Giuseppe Masucci** | Department of Oncology-Pathology, and KcRN, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

**Ignacio Melero** | CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

**Nicola Mozzillo** | Director of the Department of Melanoma and Soft Tissue, Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy

**Giuseppe Palmieri** | Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

**Igor Puzanov** | Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee

**Alessandro Testori** | Dermato-oncology Surgery Division, European Institute of Oncology, Milan, Italy

**Magdalena Thurin** | Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland



**E.C.M.**  
Commissione Nazionale Formazione Continua



### CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Provider (code 327) and has a quality-management system that meets the requirements of UNI EN ISO 9001:2008, with CSQA certificate no. 23887.

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Immunotherapy Bridge has been accredited with 1.4 CME credits for 200 participants of the following professions: Medical Doctors, Pharmacists, Biologists, and Nurses.

The number of attendees can not exceed the number of accredited participants. If the number of participants is exceeded, attendees will be admitted to the scientific sessions on the basis of registration order.

In order to receive credits, participants must:

1. Attend at least 80% of the accredited sessions
2. Complete the evaluation form at the end of the Congress
3. Complete and sign the participation statement at the end of the Congress

CME certificate attendance will be sent to the participants at the end of the evaluation procedure.

### MY ECM

Age.na.s has activated the service MyEcm (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer
2. Refer to the summary of events attended and credits earned
3. Provide an assessment of courses organized by the Provider

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.

Immunotherapy Bridge is sponsored by an unrestricted grant from:

### PLATINUM SPONSOR



**Bristol-Myers Squibb**

**MSD ONCOLOGY**

### SILVER SPONSOR



### SPONSOR



organized by:



under the auspices of:



Naples, Hotel Excelsior  
December 5<sup>th</sup>, 2015

SCIENTIFIC PROGRAM  
December 5<sup>th</sup>, 2015

IMMUNOTHERAPY BEYOND MELANOMA

Chairpersons: **Alfredo Budillon, Graham Pawelec**

09.15 AM	Predictor of response to Radiation and Immunotherapy <b>Silvia Formenti</b>
09.40 AM	Cancer vaccines revisited <b>Pedro Romero</b>
10.05 AM	Antigen-specific T cells, MDSCs and survival in melanoma and breast cancer <b>Graham Pawelec</b>
10.30 AM	Checkpoint blockade in the treatment of melanoma and neuroblastoma; effect on T cell activation and MDSCs <b>Rolf Kiessling</b>
10.55 AM	Break
11.10 AM	Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment <b>Maria Libera Ascierto</b>
11.35 AM	Understanding and combining CD137-targeted immunotherapy <b>Ignacio Melero</b>
12.00 PM	Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patients <b>Sacha Gnjatic</b>
12.25 PM	Anti-cancer immunity despite T cell "exhaustion" <b>Daniel Speiser</b>
12.50 PM	Lunch



IMMUNOTHERAPY IN ONCOLOGY (I-O): DATA FROM CLINICAL TRIAL

Chairpersons: **Filippo de Braud, Cesare Gridelli**

01.50 PM	What we learned from Immunotherapy in the past years <b>Paolo A. Ascierto</b>
02.15 PM	The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) <b>Vera Hirsh</b>
02.40 PM	Immune checkpoint inhibition in kidney cancer <b>Hans Joerg Hammers</b>
03.05 PM	Break
03.20 PM	Immunotherapy for Breast Cancer <b>Rita Nanda</b>
03.45 PM	Immunotherapy for Hemato-Oncology <b>Antonello Pinto</b>
04.10 PM	Immunotherapy in Ovarian Cancer <b>Sandro Pignata</b>
04.35 PM	Discussion
05.30 PM	Conclusions



SEGRETERIA ORGANIZZATIVA E PROVIDER ECM:

**3P**  
Solution  
via Marradi 3  
20123 - Milano ITALY  
+39 02 36631574  
www.3psolution.it



FACULTY

**Maria Libera Ascierto** | Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland

**Paolo A. Ascierto** | Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, Italy

**Alfredo Budillon** | Experimental Pharmacology Unit, Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, Italy

**Filippo de Braud** | National Cancer Institute of Milan, Italy

**Silvia Formenti** | Department of Radiation Oncology, Weill Cornell Medical College, New York

**Sacha Gnjatic** | Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai, New York

**Cesare Gridelli** | "S.G. Moscati" Hospital, Avellino, Italy

**Hans Joerg Hammers** | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

**Vera Hirsh** | McGill University, Royal Victoria Hospital, Montreal, Canada

**Rolf Kiessling** | Karolinska Institutet, Stockholm, Sweden

**Ignacio Melero** | CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

**Rita Nanda** | Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois

**Graham Pawelec** | Second Deperment of Internal Medicine, University of Tuebingen, Tuebingen, Germany

**Sandro Pignata** | Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, Italy

**Antonello Pinto** | Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, Italy

**Pedro Romero** | Ludwig Center for Cancer Research, University of Lausanne, Switzerland

**Daniel Speiser** | Department of Oncology and Ludwig Cancer Research Center, University of Lausanne, Switzerland